AxoGen, Inc.
NASDAQ:AXGNMedical - Devices
+$0.25 today
- Market cap
- $3.40B
- Beta
- 1.12
- P/E (TTM)
- -73.4
- EPS (TTM)
- -$0.61
Volume 2.11M
Average 1.08M
AXGN Debt Repayment
Cash used to repay borrowings during the period.
AxoGen, Inc.NASDAQ: AXGN
Debt Repayment · Q3 FY2026 · quarter ended Sep 2026
Debt repayment turns positive
Q3 FY2026 debt repayment was $0, compared with -$3K a year earlier. Trailing-twelve-month debt repayment was -$69.78M. Over 3 fiscal years it compounded at +38.7% a year.
Context
- Debt repayment amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Debt repayment grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$17.44M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- (32K) USD
- Year-over-year change
- -220.0%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (32K) | -220.0% |
| FY2024 | 2024-12-31 | (10K) | +0.0% |
| FY2023 | 2023-12-31 | (10K) | +16.7% |
| FY2022 | 2022-12-31 | (12K) | -100.1% |
| FY2021 | 2021-12-31 | 14.99M | — |
Debt Repayment vs competitors
How AXGN compares with its peers on the latest reported figures
- AXGN's LTM Sep 2026 debt repayment of $69.78M is the largest of the 7 companies compared; the peer median is $637.5K.
- Its year-over-year change of +465093.3% is the highest of 6, against a peer median of -83.8%.
- Debt repayment amounts to 26.1% of revenue for AXGN, versus a peer median of 17.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $69.78M | +465093.3% | +38.7% | 26.1% | |
| LTM Mar 2026 | $37.07M | +44233.3% | — | 1838.9% | |
| LTM Mar 2026 | $21.72M | -466.6% | +217.7% | 17.8% | |
| LTM Jun 2026 | $14.03M | — | +11.9% | 17.6% | |
| LTM Mar 2026 | $10.73M | -83.8% | -27.0% | 2.1% | |
| LTM Mar 2026 | $1.13M | -46.1% | +190.0% | 0.3% | |
| LTM Jun 2026 | $150K | -88.2% | — | — | |
| Peer median (excluding AXGN) | $637.5K | -83.8% | +101.0% | 17.6% | |
Competitors are the stored peer set for AXGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.99M) | (28.95M) | (21.72M) | (9.96M) | (15.7M) |
| Depreciation & Amortization | 4.74M | 4.85M | 5.55M | 7.84M | 8.19M |
| Deferred Income Tax | 3.37M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.92M | 15.59M | 14.42M | 15.91M | 30.11M |
| Change in Working Capital | (6.28M) | (9.56M) | (4.39M) | (10.04M) | (24.62M) |
| Accounts Receivables | (499K) | (4.64M) | (2.69M) | 392K | (2.46M) |
| Inventory | (7.48M) | (3.66M) | (6.05M) | (10.16M) | (9.19M) |
| Accounts Payables | (270K) | 660K | 6.51M | 125K | (7.16M) |
| Other Working Capital | 1.97M | (1.93M) | (2.15M) | (399K) | (5.81M) |
| Other Non-Cash Items | 831K | 2M | 415K | 797K | 2.83M |
| Operating Cash Flow | (13.41M) | (16.07M) | (5.72M) | 4.54M | 812K |
| Capital Expenditures | (28.4M) | (21.25M) | (14.92M) | (4.52M) | (3.75M) |
| Acquisitions (Net) | (589K) | 3.2M | 0 | 0 | 0 |
| Purchases of Investments | (68.7M) | (39.25M) | (10.2M) | (5.77M) | (13.72M) |
| Sales of Investments | 72.5M | 57.3M | 44.37M | 0 | 14M |
| Other Investing Activities | 1.54M | (3.2M) | (1.05M) | (1.42M) | (1.85M) |
| Investing Cash Flow | (23.65M) | (3.2M) | 19.25M | (10.3M) | (5.32M) |
| Debt Repayment | 14.99M | (12K) | (10K) | (10K) | (32K) |
| Common Stock Issued | 5.47M | 1.81M | 1.96M | 2.3M | 10.53M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 20.45M | 1.79M | 1.95M | 2.29M | 10.5M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (16.6M) | (17.47M) | 15.49M | (3.47M) | 5.99M |
| Free Cash Flow | (41.81M) | (37.32M) | (20.63M) | 11K | (2.93M) |
AxoGen, Inc.
NASDAQ:AXGN
Intrinsic Alpha fair value
Locked
Current Price
$56.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.